Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +203.29% | +37.36% | +4.02% | +96.38% | -2.59% |
| Gross Profit Growth | +247.35% | +63.79% | +25.19% | +99.85% | -1.74% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +7.99% | +15.94% | +23.59% | +20.94% | +21.19% |
| Weighted Average Shares Diluted Growth | +7.99% | +15.94% | +23.59% | +20.94% | +21.19% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -6.25% | -14.36% | +176.62% | +8.94% | -68.64% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -9.00% | +12.08% | +3.01% | -11.68% | -7.20% |
| Book Value per Share Growth | -10.02% | +6.60% | -11.68% | -41.43% | -72.52% |
| Debt Growth | -10.71% | -14.84% | -31.04% | -27.01% | -4.69% |
| R&D Expense Growth | -15.24% | -11.64% | +4.22% | +8.30% | +3.15% |
| SG&A Expenses Growth | +9.13% | +6.18% | +0.27% | +4.52% | -4.97% |